Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7

Vaccine

Volumn 28, Issue 27, 2010, Pages 4384-4393

  Caldeira, Jerri do Carmo ^a   Medford, Alexander ^a   Kines, Rhonda C ^b   Lino, Christopher A ^a   Schiller, John T ^b   Chackerian, Bryce ^a   Peabody, David S ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Bacteriophage; HPV vaccine; VLP

Indexed keywords

CAPSID PROTEIN; COAT PROTEIN; EPITOPE; GLYCOPROTEIN GP 120; PEPTIDE; WART VIRUS VACCINE;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONDYLOMA ACUMINATUM; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 45; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; RNA PHAGE; VACCINATION; VIRUS IMMUNITY; VIRUS LIKE AGENT; VIRUS NEUTRALIZATION;

AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; CAPSID PROTEINS; EPITOPES; FEMALE; MICE; MOLECULAR SEQUENCE DATA; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PEPTIDE LIBRARY; PEPTIDES; RNA PHAGES; SEQUENCE ALIGNMENT;

EID: 77952745199     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.04.049     Document Type: Article

References (53)

1. Chackerian B. Virus-like particles: flexible platforms for vaccine development. Expert Rev Vaccines 6 June (3) (2007) 381-390
2. Spohn G., and Bachmann M.F. Exploiting viral properties for the rational design of modern vaccines. Expert Rev Vaccines 7 Feb (1) (2008) 43-54
3. Chang M.H., Chen C.J., Lai M.S., Hsu H.M., Wu T.C., Kong M.S., et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 336 June (26) (1997) 1855-1859
4. Romanowski B., de Borba P.C., Naud P.S., Roteli-Martins C.M., De Carvalho N.S., Teixeira J.C., et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 374 December (9706) (2009) 1975-1985
5. Herbst-Kralovetz M., Mason H.S., and Chen Q. Norwalk virus-like particles as vaccines. Expert Rev Vaccines 9 March (3) (2010) 299-307
6. Quan F.S., Vunnava A., Compans R.W., and Kang S.M. Virus-like particle vaccine protects against 2009 H1N1 pandemic influenza virus in mice. PLoS ONE 5 2 (2010) e9161
7. Bachmann M.F., Lutz M.B., Layton G.T., Harris S.J., Fehr T., Rescigno M., et al. Dendritic cells process exogenous viral proteins and virus-like particles for class I presentation to CD8+ cytotoxic T lymphocytes. Eur J Immunol 26 Nov (11) (1996) 2595-2600
8. Fifis T., Gamvrellis A., Crimeen-Irwin B., Pietersz G.A., Li J., Mottram P.L., et al. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol 173 September (5) (2004) 3148-3154
9. Moron G., Rueda P., Casal I., and Leclerc C. CD8alpha-CD11b+ dendritic cells present exogenous virus-like particles to CD8+ T cells and subsequently express CD8alpha and CD205 molecules. J Exp Med 195 10 (2002) 1233-1245
10. Chackerian B., Durfee M.R., and Schiller J.T. Virus-like display of a neo-self antigen reverses B cell anergy in a B cell receptor transgenic mouse model. J Immunol 180 May (9) (2008) 5816-5825
11. Fehr T., Bachmann M.F., Bucher E., Kalinke U., Di Padova F.E., Lang A.B., et al. Role of repetitive antigen patterns for induction of antibodies against antibodies. J Exp Med 185 10 (1997) 1785-1792
12. Milich D.R., Chen M., Schodel F., Peterson D.L., Jones J.E., and Hughes J.L. Role of B cells in antigen presentation of the hepatitis B core. Proc Natl Acad Sci USA 94 December (26) (1997) 14648-14653
13. Jennings G.T., and Bachmann M.F. Immunodrugs: therapeutic VLP-based vaccines for chronic diseases. Annu Rev Pharmacol Toxicol 49 (2009) 303-326
14. Whitacre D.C., Lee B.O., and Milich D.R. Use of hepadnavirus core proteins as vaccine platforms. Expert Rev Vaccines 8 November (11) (2009) 1565-1573
15. Bachmann M.F., Rohrer U.H., Kundig T.M., Burki K., Hengartner H., and Zinkernagel R.M. The influence of antigen organization on B cell responsiveness. Science 262 5138 (1993) 1448-1451
16. Chackerian B., Lenz P., Lowy D.R., and Schiller J.T. Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. J Immunol 169 11 (2002) 6120-6126
17. Chackerian B., Lowy D.R., and Schiller J.T. Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles. Proc Natl Acad Sci USA 96 (1999) 2373-2378
18. Chackerian B., Lowy D.R., and Schiller J.T. Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J Clin Invest 108 August (3) (2001) 415-423
19. Maurer P., Jennings G.T., Willers J., Rohner F., Lindman Y., Roubicek K., et al. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur J Immunol 35 July (7) (2005) 2031-2040
20. Ambuhl P.M., Tissot A.C., Fulurija A., Maurer P., Nussberger J., Sabat R., et al. A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens 25 January (1) (2007) 63-72
21. Li Q., Cao C., Chackerian B., Schiller J., Gordon M., Ugen K.E., et al. Overcoming antigen masking of anti-amyloidbeta antibodies reveals breaking of B cell tolerance by virus-like particles in amyloidbeta immunized amyloid precursor protein transgenic mice. BMC Neurosci 5 June (1) (2004) 21
22. Peabody D.S., Manifold-Wheeler B., Medford A., Jordan S.K., do Carmo Caldeira J., and Chackerian B. Immunogenic display of diverse peptides on virus-like particles of RNA phage MS2. J Mol Biol 380 June (1) (2008) 252-263
23. Caldeira J.C., and Peabody D.S. Stability and assembly in vitro of bacteriophage PP7 virus-like particles. J Nanobiotechnology 5 (2007) 10
24. Olsthoorn R.C., Garde G., Dayhuff T., Atkins J.F., and Van Duin J. Nucleotide sequence of a single-stranded RNA phage from Pseudomonas aeruginosa: kinship to coliphages and conservation of regulatory RNA structures. Virology 206 January (1) (1995) 611-625
25. Stanley M., Lowy D.R., and Frazer I. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms. Vaccine 24 August (Suppl. 3: S3) (2006) 106-113
26. Mao C., Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Wiley D.J., et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 107 January (1) (2006) 18-27
27. Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Barr E., Alvarez F.B., et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347 21 (2002) 1645-1651
28. Roden R.B., Yutzy W.I., Fallon R., Inglis S., Lowy D.R., and Schiller J.T. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology 270 2 (2000) 254-257
29. Pastrana D.V., Gambhira R., Buck C.B., Pang Y.Y., Thompson C.D., Culp T.D., et al. Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology 337 July (2) (2005) 365-372
30. Gambhira R., Jagu S., Karanam B., Gravitt P.E., Culp T.D., Christensen N.D., et al. Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. J Virol 81 November (21) (2007) 11585-11592
31. Lim F., Downey T.P., and Peabody D.S. Translational repression and specific RNA binding by the coat protein of the Pseudomonas phage PP7. J Biol Chem 276 June (25) (2001) 22507-22513
32. Peabody D.S. Translational repression by bacteriophage MS2 coat protein expressed from a plasmid. A system for genetic analysis of a protein-RNA interaction. J Biol Chem 265 April (10) (1990) 5684-5689
33. Gambhira R., Karanam B., Jagu S., Roberts J.N., Buck C.B., Bossis I., et al. A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J Virol 81 December (24) (2007) 13927-13931
34. Roberts J.N., Buck C.B., Thompson C.D., Kines R., Bernardo M., Choyke P.L., et al. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med 13 July (7) (2007) 857-861
35. Johnson K.M., Kines R.C., Roberts J.N., Lowy D.R., Schiller J.T., and Day P.M. Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus. J Virol 83 March (5) (2009) 2067-2074
36. Cuburu N., Kweon M.N., Hervouet C., Cha H.R., Pang Y.Y., Holmgren J., et al. Sublingual immunization with nonreplicating antigens induces antibody-forming cells and cytotoxic T cells in the female genital tract mucosa and protects against genital papillomavirus infection. J Immunol 183 December (12) (2009) 7851-7859
37. Tars K., Fridborg K., Bundule M., and Liljas L. The three-dimensional structure of bacteriophage PP7 from Pseudomonas aeruginosa at 3.7-A resolution. Virology 272 July (2) (2000) 331-337
38. Laman J.D., Schellekens M.M., Abacioglu Y.H., Lewis G.K., Tersmette M., Fouchier R.A., et al. Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptides from the gp120 third variable domain. J Virol 66 Marc (3) (1992) 1823-1831
39. Peabody D.S. Subunit fusion confers tolerance to peptide insertions in a virus coat protein. Arch Biochem Biophys 347 November (1) (1997) 85-92
40. Alphs H.H., Gambhira R., Karanam B., Roberts J.N., Jagu S., Schiller J.T., et al. Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc Natl Acad Sci USA 105 April (15) (2008) 5850-5855
41. Slupetzky K., Shafti-Keramat S., Lenz P., Brandt S., Grassauer A., Sara M., et al. Chimeric papillomavirus-like particles expressing a foreign epitope on capsid surface loops. J Gen Virol 82 November (Pt 11) (2001) 2799-2804
42. Smith M.L., Lindbo J.A., Dillard-Telm S., Brosio P.M., Lasnik A.B., McCormick A.A., et al. Modified tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applications. Virology 348 May (2) (2006) 475-488
43. Arnold G.F., Velasco P.K., Holmes A.K., Wrin T., Geisler S.C., Phung P., et al. Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope. J Virol 83 May (10) (2009) 5087-5100
44. Billaud J.N., Peterson D., Barr M., Chen A., Sallberg M., Garduno F., et al. Combinatorial approach to hepadnavirus-like particle vaccine design. J Virol 79 November (21) (2005) 13656-13666
45. Ekiert D.C., Bhabha G., Elsliger M.A., Friesen R.H., Jongeneelen M., Throsby M., et al. Antibody recognition of a highly conserved influenza virus epitope. Science 324 April (5924) (2009) 246-251
46. Sui J., Hwang W.C., Perez S., Wei G., Aird D., Chen L.M., et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16 March (3) (2009) 265-273
47. Law M., Maruyama T., Lewis J., Giang E., Tarr A.W., Stamataki Z., et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 14 January (1) (2008) 25-27
48. Burton D.R., Stanfield R.L., and Wilson I.A. Antibody vs. HIV in a clash of evolutionary titans. Proc Natl Acad Sci USA 102 October (42) (2005) 14943-14948
49. Slupetzky K., Gambhira R., Culp T.D., Shafti-Keramat S., Schellenbacher C., Christensen N.D., et al. A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. Vaccine 25 March (11) (2007) 2001-2010
50. Palmer K.E., Benko A., Doucette S.A., Cameron T.I., Foster T., Hanley K.M., et al. Protection of rabbits against cutaneous papillomavirus infection using recombinant tobacco mosaic virus containing L2 capsid epitopes. Vaccine 24 June (26) (2006) 5516-5525
51. Jagu S., Karanam B., Gambhira R., Chivukula S.V., Chaganti R.J., Lowy D.R., et al. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst 101 June (11) (2009) 782-792
52. Nardelli-Haefliger D., Lurati F., Wirthner D., Spertini F., Schiller J.T., Lowy D.R., et al. Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine. Vaccine 23 May (28) (2005) 3634-3641
53. Hunter Z., Smyth H.D., Durfee P., and Chackerian B. Induction of mucosal and systemic antibody responses against the HIV coreceptor CCR5 upon intramuscular immunization and aerosol delivery of a virus-like particle based vaccine. Vaccine 28 December (2) (2009) 403-414